SCHEMBL5230239

SCHEMBL5230239

COc1ccc(S(=O)(=O)N(C)C)cc1Nc1ncc(-c2ccc(F)cc2)o1

nearest known ligand 0.77

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.77
FLT1 P17948 16/20 0.77
FLT4 P35916 16/20 0.77
CLK1 P49759 1/20 0.57
DYRK1A Q13627 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234676 0.89 KDR (0.81) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5186912 0.88 KDR (0.80) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5224832 0.87 KDR (1.00) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5468487 0.87 KDR (0.78) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5472964 0.86 KDR (0.77) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5222950 0.86 FLT1 (0.56) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5465187 0.85 KDR (0.79) KDRFLT1FLT4
SCHEMBL5472518 0.84 KDR (0.74) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5476174 0.83 KDR (0.82) KDRFLT1FLT4CLK1DYRK1A
SCHEMBL5472775 0.83 KDR (0.79) KDRFLT1FLT4CLK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551813-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-07-11 EP claimed
EP-1179532-B1 PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR EISAI R&D MAN CO LTD (JP) 2007-06-13 EP claimed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US claimed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US claimed
EP-1551813-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-13 EP claimed
WO-2004032882-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-22 WO claimed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
EP-1179532-B1 PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR EISAI R&D MAN CO LTD (JP) 2007-06-13 EP disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US disclosed
EP-1179532-A4 PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR EISAI CO LTD (JP) 2004-10-20 EP disclosed
WO-2000061575-A1 PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR EISAI CO., LTD. (JP) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 KDR 33/4885FLT1 56/4885FLT4 47/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 KDR 33/4885FLT1 56/4885FLT4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.